#USA #New York #class action lawsuit #Pomerantz Law Firm #Capricor Therapeutics

Investors Alert: Capricor Therapeutics Class Action Lawsuit

The legal landscape surrounding Capricor Therapeutics, Inc. has recently become turbulent due to a class action lawsuit filed by Pomerantz LLP. Investors who have suffered losses as a result of their stakes in Capricor are now urged to take action before the looming deadlines. This article provides an overview of the situation, the allegations at hand, and what affected investors need to know moving forward.

Background Information

Capricor Therapeutics, known for its development of innovative therapies for Duchenne muscular dystrophy (DMD), has been under scrutiny following critical feedback from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for the therapeutic product Deramiocel. As the company navigates these challenges, investors are rightfully concerned about the potential implications for their investments and whether they have grounds to pursue legal action.

Class Action Details

Pomerantz LLP has taken the initiative to file a class action lawsuit against Capricor. According to the firm, the lawsuit questions whether Capricor's management has engaged in securities fraud or other unlawful practices that have misled investors about the viability of its products and lead to significant financial losses.

Important Dates

Affected parties must act quickly, as the deadline to seek appointment as Lead Plaintiff is set for September 28, 2026. Interested investors are encouraged to contact Pomerantz directly to discuss their cases and perhaps join the class action effort.

The FDA's Response to Capricor

In a significant turn of events, the FDA communicated its concerns about the BLA in July 2025 and indicated that it was not ready to approve the application. The FDA's Complete Response Letter (CRL) cited that the application did not meet statutory requirements mandating sufficient evidence of effectiveness, which left the company scrambling to address the issues raised.

As Capricor publicly stated, it believed it could rectify these concerns by March 2026. However, a recent advisory meeting held by the FDA's advisory committee revealed that significant issues remained unresolved. Specifically, the committee criticized the company for making changes to its statistical analysis plan that were not pre-approved, which raised questions about the integrity of the trial data presented.

The FDA's findings indicated a negative benefit-risk assessment for Deramiocel, citing a lack of evidence supporting its effectiveness. As a result, those developments saw Capricor's stock plummet by 64% on July 27, 2026, further solidifying the case for investor loss and dissatisfaction.

Market Reaction

After the advisory committee's non-binding vote against the efficacy of Deramiocel, Capricor’s stock price suffered another blow, falling by 36% the following day. These sudden drops in stock value have understandably caused distress among shareholders, particularly those who trusted the company to deliver on its promises based on its previous communications.

This scenario starkly illustrates the potential consequences of managerial decisions in the pharmaceutical landscape—and raises awareness for current and prospective investors concerning the risks associated with investing in biotech firms undergoing regulatory scrutiny.

The Role of Pomerantz LLP

With a venerable history in securities litigation, Pomerantz LLP has established itself as a leading law firm dedicated to defending the rights of investors. Founded by Abraham L. Pomerantz, known for both his legal acumen and pioneering efforts in class action suits, the firm continues to champion issues of security fraud and corporate malfeasance.

Investors who believe they may have been affected by Capricor’s actions should consider engaging Pomerantz LLP or legal counsel immediately. The firm is currently preparing for litigation and aims to hold individuals accountable for any proven obligations in misleading stakeholders.

Conclusion

In light of the Capricor situation and the ensuing class action lawsuit, investors must remain vigilant and informed about their rights and avenues for action. Awareness of the situation and proactive engagement can be critical in pursuing financial restitution amidst these unfolding events. It serves as a poignant reminder of the responsibility companies hold toward their investors and the potential ramifications of failing to uphold these duties.

For additional information or to discuss your potential involvement in the class action lawsuit against Capricor Therapeutics, please reach out to Danielle Peyton at Pomerantz LLP. For anyone affected or interested in learning more, don’t hesitate to act quickly as deadlines draw near.